Beijing Tiantan Biological Products Co., Ltd. (SHSE: 600161)
Health Care · Biotechnology · CN
CN¥12.15
-3.11% today · -41.1% 1Y
Beijing Tiantan Biological Products Co., Ltd. (SHSE: 600161) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.57B and employs 5,205 people.
Over the last twelve months the share price has lost 41.1%, trading between 11.12 and 20.77.
Tweenvest scores Beijing Tiantan Biological Products Co., Ltd. across four factors: quality 80/100, value 54/100, growth 61/100, dividend 44/100. Its strongest factor is quality.
600161 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.57B
- Revenue (TTM)
- $868.73M
- P/E
- 24.98
- EPS
- 0.49
- Dividend yield
- 1.65%
- Beta (5Y)
- 0.22
- 52-week high
- CN¥20.77
- 52-week low
- CN¥11.12
- Avg volume (3M)
- —
- Shares outstanding
- 1.98B
- Employees
- 5,205
- Next earnings
- —
About Beijing Tiantan Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
- ISIN
- CNE000000WF9
- Founded
- 1966
- Listed since
- Jun 16, 1998
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.